Piramal Pharma logo

Piramal Pharma financials: balance sheet, profit and loss, cash flow

NSE: PPLPHARMABSE: 543635Pharmaceuticals & BiotechnologySmall Cap

Piramal Pharma Limited · Face value ₹10 · Listed Oct 2022
Last close ₹232.80up ₹34.08 (17.15%)BSE ₹232.80

Share price at the NSE close on 28 Oct 2026. Previous close ₹198.72.

28 Oct: open ₹214.10, high ₹235.64, low ₹209.04

52-week range of traded prices to 28 Oct 2026
₹132.30Low, 23 Mar 2026₹235.64High, 28 Oct 2026
Market cap
₹30,994 Cr331st largest listed
P/E
Lossover the last 12 months
P/B
3.81
Dividend yield
Nonein the last 12 months
ROE
−2.6%
ROE without one-offs
0.1%
ROCE
2.3%
Debt to equity
0.69
Volume, NSE
11,80,72,22815.7% delivered

Piramal Pharma's financial statements for the 4 years to Mar 2026, consolidated: the company and its subsidiaries together, with the half year to Sep 2026 after them.

4 years at a glance

₹ crore, years to March.Piramal Pharma annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
7,082−1865,505Mar 238,171184,559Mar 249,151914,720Mar 258,869−3265,495Mar 26
Peak revenue ₹9,151 Cr, year to Mar 2025; lowest ₹7,082 Cr, year to Mar 2023A loss in the year to Mar 2026, −₹326 Cr

Operating and net margin, per cent

  • Operating margin
  • Net margin
15.8%−3.7%8.9%14.6%15.8%10.4%−2.6%0.2%1.0%−3.7%Mar 23Mar 24Mar 25Mar 26

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue8,869
  2. Materials and goods−3,239
  3. Employee costs−2,416
  4. Other expenses−2,293
  5. Operating profit922
  6. Depreciation−831
  7. Other income+213
  8. One-off items−196
  9. Finance costs−341
  10. Profit before tax−233
  11. Tax−150
  12. Joint ventures+57
  13. Net profit−326

What the company owns

  • Plant, investments and other assets₹11,388 Cr
  • Inventory₹3,064 Cr
  • Receivables₹2,158 Cr
  • Cash and bank₹1,224 Cr
  • Current investments₹132 Cr

What pays for it: net worth and liabilities

  • Net worth₹8,163 Cr
  • Borrowings₹5,495 Cr
  • Owed to suppliers₹2,479 Cr
  • Other liabilities₹1,828 Cr

Profit and loss

Consolidated, ₹ crore, years to March. The last column is the twelve months to Sep 2026, the latest four quarters added.Piramal Pharma quarterly results

₹ croreMar 2023Mar 2024Mar 2025Mar 2026Sep 2026Twelve monthsFiled 27 Oct
Revenue from operations7,0828,1719,1518,8699,779
6,4536,9757,7067,9478,578
Materials and goods bought2,7032,9543,2323,2393,600
Employee costs1,8962,0302,3072,4162,576
Other expenses1,8541,9912,1672,2932,402
Operating profit before depreciation6281,1961,4459221,200
Operating margin8.9%14.6%15.8%10.4%12.3%
Materials, % of revenue38.2%36.2%35.3%36.5%36.8%
Employee costs, % of revenue26.8%24.8%25.2%27.2%26.3%
Other expenses, % of revenue26.2%24.4%23.7%25.9%24.6%
Depreciation and amortisation677741816831888
Operating profit after depreciation−4845662890312
Other income225175135213215
Finance costs344448422341348
Profit before one-off items and tax−168183342−37179
One-off items−7−630−196−217
Profit before tax−174120342−233−38
66161324150233
Share of profit of joint ventures and associates5459735761
−1861891−326−209
Other comprehensive income1765780338237
Total comprehensive income−11751711227
Net margin−2.6%0.2%1.0%−3.7%−2.1%
Net margin without joint ventures and associates−3.4%−0.5%0.2%−4.3%–

Balance sheet

Consolidated, ₹ crore, at 31 March. The last column is the half year to Sep 2026, after the latest full year: the balance sheet at its end.

₹ croreMar 2023Mar 2024Mar 2025Mar 2026Sep 2026Half yearFiled 27 Oct
6,7747,9118,1258,1638,165
6,7747,9118,1258,1638,142
Share capital1,1931,3231,3241,3271,328
Reserves5,5806,5886,8016,8356,814
Belonging to outside owners of subsidiaries––0022
5,5054,5594,7205,4955,665
3,8434,3693,7664,7585,159
3,9063,0313,7865,0445,214
Total assets14,52315,31215,67817,96518,537
9,6879,8479,88110,77311,284
4,8355,4645,7977,1927,254
Net debt4,7703,9324,1994,1404,835
Borrowings are counted again inside the liabilities due within a year and after a year. Plant in use and plant being built are given for full years only.

Cash flow

Consolidated, ₹ crore, years to March. The last column is the half year to Sep 2026, after the latest full year: the cash flow over its six months.

₹ croreMar 2023Mar 2024Mar 2025Mar 2026Sep 2026Half year
4841,0058921,653391
6731,1651,2271,863497
−295−234−488527−174
Receivables89−391−233217−44
Inventories−173−532−197−798−268
Payables−26540418778277
Other working capital53285−75329−139
Tax paid−189−157−334−210−107
Capital spending965712664890859
Free cash flow−481293228763−468
−1,339−434−477−826−970
818−422−441−39−131
Dividends paid67014190
Shares bought back014000
Shares issued01,050000
Net change in cash−37148−26788−711
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only.

Per share

Consolidated, ₹ per share, years to March.Piramal Pharma dividend history

₹ per shareMar 2023Mar 2024Mar 2025Mar 2026
Earnings per share−₹1.57₹0.14₹0.69−₹2.46
Diluted earnings per share−₹1.57₹0.14₹0.68−₹2.46
Dividend per share–₹0.11₹0.14–
Book value per share₹56.76₹59.80₹61.35₹61.50
Dividend payout–81.7%20.3%–
Shareholder yield0.8%−6.1%0.0%0.1%
Market cap at the year end (₹ crore)8,16817,05329,79618,150

Ratios

Consolidated, years to March.Piramal Pharma PE ratio and valuation

RatioMar 2023Mar 2024Mar 2025Mar 2026
Revenue growth–15.4%12.0%−3.1%
Operating profit growth–90.4%20.8%−36.2%
Net profit growth––411.4%–
Earnings per share growth––392.9%–
−2.8%0.2%1.1%−4.0%
–3.0 pts0.9 pts−5.1 pts
From the net margin–3.0 pts0.9 pts−5.3 pts
From asset turnover–0.0 pts0.1 pts0.4 pts
From borrowing–0.0 pts−0.1 pts−0.3 pts
Return on capital employed−0.4%3.7%4.9%0.7%
Cash conversion–5,637.1%979.2%–
Interest cover–1.01.50.3
Debt to equity0.810.580.580.67
Receivable days93959489
Inventory days227269261345
Payable days161190173279
Cash conversion cycle, days159174182155
Working capital days12311412094
Asset turnover0.490.550.590.53
Assets per rupee of net worth2.142.031.932.07
Sales per rupee of plant2.112.112.191.99
Capital spending to depreciation1.430.960.811.07
Plant being built, % of plant in use25.4%14.6%11.7%18.0%
Interest cover is left blank for the year to Mar 2023: operating profit after depreciation is a loss, and a loss covers no interest bill.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
−1.9%
Cash from operations against operating profit
179.3%
Measure5 years3 years
Revenue growth, yearly rate–7.8%
Return on equity, average−1.3%−0.9%
Return on capital employed, average2.2%3.1%
Operating margin, average12.4%13.6%
Net margin, average−1.3%−0.8%
Asset turnover, average0.540.56
Cash conversion cycle, days, average167170
Interest cover, average–0.9
Debt to equity, average0.660.61

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore3 yearsLatest year
Cash from operations3,5491,653
Cash from investing−1,738−826
Cash from financing−902−39
Capital spending2,266890
Dividends paid3319
Shares bought back140
Shares issued for cash1,0500
Borrowings raised8,2081,887
Borrowings repaid8,8101,567

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––72
Altman Z-scorePublished threshold 1.811.782.733.872.32
Beneish M-scorePublished threshold −1.78–−2.65−2.66−3.12
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–−3.71−2.09−6.85
Receivables growth less revenue growthOur threshold 0 percentage points–3.24−1.92−5.08
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–20.14−3.1132.29
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–−1.140.950.00
Assets under construction, years of additionsOur threshold 2 years of additions–0.450.440.72
Effective tax ratePublished threshold 17.16 per cent–134.7894.67–
Tax charged less tax paid, % of profitOur threshold 10 percentage points–3.86−3.18–
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
17 Jul 2026CARE Ratings LimitedFund-based - ST-Line of CreditCARE A1+Review, Re-affirm100
17 Jul 2026CARE Ratings LimitedLT/ST Fund-based/Non-fund-based-EPC / PCFC / FBP / FBD / WCDL / OD / BG / SBLCCARE AA / CARE A1+Review, Re-affirmStable1,503
17 Jul 2026CARE Ratings LimitedFund-based - LT-Term LoanCARE AAReview, Re-affirmStable1,297
17 Jul 2026CARE Ratings LimitedDebentures-Non Convertible DebenturesCARE AAReview, Re-affirmStable66.67
17 Jul 2026CARE Ratings LimitedIssuer RatingCARE AAReview, Re-affirmStable
17 Jul 2026CARE Ratings LimitedCommercial PaperCARE A1+Review, Re-affirm200
15 Oct 2025ICRA LimitedCommercial Paper[ICRA]A1+Review, Other100
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.